Shikari® (S-ATT) Anti-Trastuzumab ELISA
Enzyme immunoassay for the qualitative determination of specific antibodies to Trastuzumab (Herceptin®, Herclon®) in serum and plasma.
This kit has been especially developed for the qualitative determination of specific antibodies to Trastuzumab in serum and plasma samples.
The Matriks Biotek Antibody to Trastuzumab Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the qualitative determination of antibodies to Trastuzumab in serum and plasma.Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact firstname.lastname@example.org
|Required Volume (µl)||20|
|Total Time (min)||140|
|Detection Limit (ng/mL)||+ / -|
|Spike Recovery (%)||-|
|Shelf Life (year)||1|
|Storage conditions||Store at +4°C. Please refer to protocols.|
|Shipping conditions||At room temperature|
|Instructions For Use||Download|
|Safety Data Sheet (SDS)||Download|
Publications with this drug
|Mocenigo, Marco, et al. "Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples." ACS sensors 5.10 (2020): 3109-3115.||Visit Link|
|Padrón, Ivette Mourani, et al. "Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer." Journal of Oncology Pharmacy Practice (2020): 1078155220953873.||Visit Link|
|González García, Jonathan, et al. "Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients." Annals of Pharmacotherapy (2020): 1060028020902318.||Visit Link|
|Puente‐Massaguer, Eduard, et al. "A statistical approach to improve compound screening in cell culture media." Engineering in Life Sciences 19.4 (2019): 315-327.||Visit Link|
|González-García, J., et al. "Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions." Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 43.2 (2019): 50-52.||Visit Link|
|González García, Jonathan, et al. "Influence of anthropometric characteristics in patients with Her2-positive breast cancer on initial plasma concentrations of trastuzumab." Annals of Pharmacotherapy 51.11 (2017): 976-980.||Visit Link|
|Iwamoto, Noriko, Akinobu Hamada, and Takashi Shimada. "Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis." Analytical biochemistry 540 (2018): 30-37.||Visit Link|
|Jing Chen et. al., "Tailor-Making Fluorescent Hyaluronic Acid Microgels via Combining Microfluidics and Photoclick Chemistry for Sustained and Localized Delivery of Herceptin in Tumor." ACS Appl. Mater. Interfaces, (2018).||Visit Link|
|Kevin H, et al, “Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies”: Oncotarget, 2018, Vol. 9, (No. 17), pp: 13623-13636.||Visit Link|
|Jonathan GG, Beatriz AÁ, Nazco C GJ, Norberto BL, Fernando GN. Plasma levels of trastuzumab in gastric cancer: Case report. J Oncol Pharm Pract. Sep 23, 2016.||Visit Link|
|Genetically modified micro-organ secreting antibody and methods of use Reem MiariNir ShapirInbal ZAFIR-LAVIE||Visit Link|
|Hollevoet, Kevin, et al. "Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep." Human Gene Therapy 30.11 (2019): 1431-1443.||Visit Link|
|Nanoparticle and Macromolecular Transfer across the Human Placental Barrier||Download|
|METHOD FOR QUANTIFYING MONOCLONAL ANTIBODY HAVIN ANTIGEN OR ANTI - ANTIBODY BONDED THERETO, Iwamoto et al.||Visit Link|